Declining childhood and adolescent cancer mortality - Wikidata - awgldk - TriplyDB

Declining childhood and adolescent cancer mortality

Declining childhood and adolescent cancer mortality

http://www.wikidata.org/entity/Q34060045

about

Advancing a comprehensive cancer care agenda for children and their families: Institute of Medicine Workshop highlights and next steps Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation Pediatric solid tumor genomics and developmental pliancy Fertility Preservation after a Cancer Diagnosis: A Systematic Review of Adolescents', Parents', and Providers' Perspectives, Experiences, and Preferences.Characterization of Alstrom Syndrome 1 (ALMS1) Transcript Variants in Hodgkin Lymphoma Cells.Mortality and survival patterns of childhood lymphomas: geographic and age-specific patterns in Southern-Eastern European and SEER/US registration data.Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.Time and spatial trends in lymphoid leukemia and lymphoma incidence and survival among children and adolescents in Manitoba, Canada: 1984-2013.MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.Final height and body mass index in adult survivors of childhood acute lymphoblastic leukemia treated without cranial radiotherapy: a retrospective longitudinal multicenter Italian study AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia Declining childhood and adolescent cancer mortality: great progress but still much to be done.Remaining challenges in childhood cancer and newer targeted therapeutics.When to say when: How aggressively to care for children with multiply relapsed cancer?Drug discovery in paediatric oncology: roadblocks to progress.Childhood hematologic cancer and residential proximity to oil and gas development.Preclinical Models Provide Scientific Justification and Translational Relevance for Moving Novel Therapeutics into Clinical Trials for Pediatric Cancer.Years of Life Lost and Childhood and Adolescent Cancer Mortality in Yazd Province, Iran (2004-2009).Oncofertility: a grand collaboration between reproductive medicine and oncology Ex vivo induction of antitumor DEC-205(+) CD11c(+) cells in a murine neuroblastoma model by co-stimulation with doxorubicin, lipopolysaccharide and interleukin-4 Immunogenicity and clinical effectiveness of the trivalent inactivated influenza vaccine in immunocompromised children undergoing treatment for cancer.Obesity and Metabolic Disease After Childhood Cancer Paediatric non-Hodgkin lymphoma in low and middle income countries.Incidence and Trend of Childhood and Adolescent Cancers in Yazd, Iran.Clinical Guidelines for the Care of Childhood Cancer Survivors.Spermatogonial Stem Cells: Implications for Genetic Disorders and Prevention.MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27 acetylation Immune-based therapies for childhood cancer.Targeted approaches to childhood cancer: progress in drug discovery and development.The Ethics of Clinical Care and the Ethics of Clinical Research: Yin and Yang.Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines.Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation.Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine.Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors.Genetic factors conferring metastasis in osteosarcoma.Identifying novel therapeutic agents using xenograft models of pediatric cancer.Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience.Demographics, patterns of care, and survival in pediatric medulloblastoma.Needs of adolescents and young adults after cancer treatment: a systematic review.Lessons from Retinoblastoma: Implications for Cancer, Development, Evolution, and Regenerative Medicine.

P2860

Q26752816-01056F95-3E87-4082-9006-5C332E88845C Q26784048-F869FCD7-665A-42D0-9A7C-A83882D329B6 Q27023560-105DDCEE-1A78-4864-9986-AC94AE716D05 Q30276923-3F27E317-0259-4EDE-88F0-7C9CACC30024 Q30313499-C63515AD-9018-4A20-9C85-83BB1C881E48 Q31131542-657DD176-4639-4BB9-8298-9C1456ED4526 Q33433407-F2FF4DFD-3B84-4A51-B824-53B2743B5A85 Q33590225-65E18C3C-EEA0-4DAD-ADF2-0FFAA38FCB3D Q33869257-34ACEF23-2B16-4AB6-88D1-2DF3AE7003D9 Q34325688-F99015BF-F3AB-47E5-82D9-9BE23664EF92 Q34482552-1B70A720-9951-464C-AE4D-D10DEB395798 Q34511492-07ADFEB3-F502-4EC4-AF45-64F4297014D3 Q35106844-04FB3BB1-E2AD-4E71-A7C4-891146E51B6C Q35612070-642BA3D2-56BB-4CCA-8E08-F79A2BB6AE6C Q36262295-75D8B375-E029-44AB-A54A-0F929A810927 Q36281097-10478105-F88A-4C08-9435-606C9BBD1966 Q36378105-3A8C12D7-B028-417B-BC2F-A434664C61A4 Q36397078-B0BD2285-62FB-4F49-84C6-4260CCBC855A Q36455946-74880DBF-39BD-4242-86DA-3FAC7FBB5285 Q36502098-53B2A4D4-2605-411D-8B49-2DF2D46769C5 Q36528351-91D59712-8016-49D7-B861-A4CB63A3267B Q36588407-60432896-D17D-47E6-A750-9C3EE9ADCC38 Q36889228-014F9BC1-4C0F-4752-B383-DDE9ECFE7FC5 Q36901701-C7CDCE0D-A9D6-4949-A316-BEDE985F0FA1 Q37055826-F3553F1E-4F1F-4122-8051-224E7A2FB8A7 Q37281655-14920C24-265A-4841-8CFC-821FF8C5750C Q37676956-FE859FAF-0D07-4D80-8BC1-62ED15883AB6 Q38263108-00882839-CAD9-4D59-A4ED-30748F7C2313 Q38404462-0D7175AA-E4BB-43B5-B6AB-EF589E07F870 Q38438338-39686D36-EA77-4CA3-AC54-B8E13C953D08 Q38643567-C7082FFD-3EAE-4F16-A293-21A33E6BC48D Q38684561-00A84A3C-A03E-4C31-97CE-A6A457BD80FF Q38792235-1ECF1071-AF3E-481D-BACB-06B79B8C1818 Q38794832-51C0C21D-9AE4-4ECE-80A6-E0CFA3C53744 Q38806986-87B4D43D-E46D-49D7-ABCA-4E6FBBB88558 Q38837564-26BE7174-722C-4C81-BF2F-8DD7B8C57E50 Q38840660-F279DC0A-5C02-412C-AB58-C68E361A6F22 Q38909956-EAE2DE74-789A-4CED-B111-95EAA48E2129 Q38923326-E4CCC129-B2BC-44CD-967D-9FA5FCFC9056 Q38938719-0CF05696-457F-4A3D-AF2E-9CA35CF440EE

P2860

Declining childhood and adolescent cancer mortality

http://www.wikidata.org/entity/Q34060045

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Declining childhood and adolescent cancer mortality

@ast

Declining childhood and adolescent cancer mortality

@en

Declining childhood and adolescent cancer mortality

@nl

type

label

Declining childhood and adolescent cancer mortality

@ast

Declining childhood and adolescent cancer mortality

@en

Declining childhood and adolescent cancer mortality

@nl

prefLabel

Declining childhood and adolescent cancer mortality

@ast

Declining childhood and adolescent cancer mortality

@en

Declining childhood and adolescent cancer mortality

@nl

P1433

Q34060045-BB9FDE65-A660-4C20-9E8B-04A93A13191C

P1476

Q34060045-07E054A7-F329-4CFB-BAF2-239FD010E457

P2093

Q34060045-01E5FF2B-6E16-45A1-B354-3F032918B42F

Q34060045-26ED2C5F-25B6-43AA-B097-33701D02634F

Q34060045-4C95C72A-4CD8-4174-96EC-A43AEB8E2793

Q34060045-60BAEB9D-485B-4656-9BD6-C03FEA94CA01

P2860

Q34060045-0F451DC1-5607-4428-BF6E-C4427256C7F3

Q34060045-1963C1B0-13D5-46D5-B5EA-2513458F6BB8

Q34060045-20938E76-47C5-4CBE-8056-1667F08328AF

Q34060045-2930C901-BA6C-4FB3-927E-2A6D8295E05B

Q34060045-2F91AD24-2669-4D3A-85C0-F47197C3AA32

Q34060045-36F9015C-270B-4F31-B1E2-EB30E02D76C3

Q34060045-426555E8-9CAE-4128-AD8C-5159F3E95506

Q34060045-493CBB17-8A65-4CEF-809D-4E26C3ADCA09

Q34060045-500DD319-7208-4E1B-8CED-70B666E10AA4

Q34060045-5FC7791F-18EB-4D76-BEDD-EB27D4A47F02

P304

Q34060045-24AE5717-C9FB-4B34-811C-A6914E2F42D6

P31

Q34060045-85B71465-928A-4A35-AB03-E796CEAC06BC

P356

Q34060045-1CDF2927-E966-4E46-9100-B643CBB50D69

P407

Q34060045-A402D6F1-0D8B-4AA8-8820-B2618E0426D8

P433

Q34060045-6872D4D2-D4CD-40A6-9516-1A9136B267C5

P478

Q34060045-265DEBF9-48EC-4622-B02A-013C65C30279

P50

Q34060045-D737458A-B451-4471-9019-F31272AE6AAF

P577

Q34060045-D3A5B9D5-A3AD-43FE-8674-62452A413D1F

P698

Q34060045-3DFF90BF-246F-4382-8FB3-DE2A914AA933

P921

Q34060045-D8E8F9E2-2D22-4A85-B9B9-DD40A268D218

P932

Q34060045-715FCF7F-79E9-4257-ABB4-DF8839C80FC7

P356

P1433

P1476

Declining childhood and adolescent cancer mortality

@en

P2093

Gregory H Reaman

http://www.w3.org/2001/XMLSchema#string

Malcolm A Smith

http://www.w3.org/2001/XMLSchema#string

Peter C Adamson

http://www.w3.org/2001/XMLSchema#string

Sean F Altekruse

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas

An integrated genomic analysis of human glioblastoma multiforme

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Outcomes for children and adolescents with cancer: challenges for the twenty-first century.

The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer

Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.

P304

2497-2506

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.28748

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24853691

http://www.w3.org/2001/XMLSchema#string

P921

P932

4136455

http://www.w3.org/2001/XMLSchema#string